Loading
A phase 2 trial of Cemiplimab in cutaneous squamous cell carcinoma, run by Replimune, Inc., active and no longer recruiting.
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer is a phase 2 interventional study registered as NCT04050436 by Replimune, Inc., with 231 participants enrolled, started 2019-10-08 and due to reach its primary completion in 2025-09. Interventions recorded: Cemiplimab, RP1. Conditions listed: Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, Cutaneous squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, Cutaneous squamous cell carcinoma.
Shares Replimune, Immune checkpoint inhibitors.
Shares Replimune, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, Cutaneous squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/